Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
18 Jun 2024
Historique:
received: 03 01 2024
accepted: 12 06 2024
medline: 12 8 2024
pubmed: 12 8 2024
entrez: 12 8 2024
Statut: epublish

Résumé

The skin at the site of HSV-2 reactivation is enriched for HSV-2-specific T cells. To evaluate whether an immunotherapeutic vaccine could elicit skin-based memory T cells, we studied skin biopsies and HSV-2-reactive CD4+ T cells from PBMCs by T cell receptor (TCR) β chain (TRB) sequencing before and after vaccination with a replication-incompetent whole-virus HSV-2 vaccine candidate (HSV529). The representation of HSV-2-reactive CD4+ TRB sequences from PBMCs in the skin TRB repertoire increased after the first vaccine dose. We found sustained expansion after vaccination of unique, skin-based T cell clonotypes that were not detected in HSV-2-reactive CD4+ T cells isolated from PBMCs. In one participant, a switch in immunodominance occurred with the emergence of a TCR αβ pair after vaccination that was not detected in blood. This TCRαβ was shown to be HSV-2 reactive by expression of a synthetic TCR in a Jurkat-based NR4A1 reporter system. The skin in areas of HSV-2 reactivation possessed an oligoclonal TRB repertoire that was distinct from the circulation. Defining the influence of therapeutic vaccination on the HSV-2-specific TRB repertoire requires tissue-based evaluation.

Identifiants

pubmed: 39133650
pii: 179010
doi: 10.1172/jci.insight.179010
doi:
pii:

Substances chimiques

Receptors, Antigen, T-Cell, alpha-beta 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : UpdateOf

Auteurs

Emily S Ford (ES)

Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
Division of Allergy and Infectious Diseases, Department of Medicine, and.

Alvason Z Li (AZ)

Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.

Kerry J Laing (KJ)

Division of Allergy and Infectious Diseases, Department of Medicine, and.

Lichun Dong (L)

Division of Allergy and Infectious Diseases, Department of Medicine, and.

Kurt Diem (K)

Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.

Lichen Jing (L)

Division of Allergy and Infectious Diseases, Department of Medicine, and.

Koshlan Mayer-Blackwell (K)

Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.

Krithi Basu (K)

Division of Allergy and Infectious Diseases, Department of Medicine, and.

Mariliis Ott (M)

Division of Allergy and Infectious Diseases, Department of Medicine, and.

Jim Tartaglia (J)

Sanofi, Swiftwater, Pennsylvania, USA.

Sanjay Gurunathan (S)

Sanofi, Swiftwater, Pennsylvania, USA.

Jack L Reid (JL)

Translational Sciences and Therapeutics Division, Fred Hutch Cancer Center, Seattle, Washington, USA.

Matyas Ecsedi (M)

Translational Sciences and Therapeutics Division, Fred Hutch Cancer Center, Seattle, Washington, USA.

Aude G Chapuis (AG)

Translational Sciences and Therapeutics Division, Fred Hutch Cancer Center, Seattle, Washington, USA.

Meei-Li Huang (ML)

Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.

Amalia S Magaret (AS)

Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.

Christine Johnston (C)

Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
Division of Allergy and Infectious Diseases, Department of Medicine, and.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.

Jia Zhu (J)

Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Institute of Stem Cell and Regenerative Medicine and.

David M Koelle (DM)

Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
Division of Allergy and Infectious Diseases, Department of Medicine, and.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Department of Global Health, University of Washington, Seattle, Washington, USA.
Benaroya Research Institute, Seattle, Washington, USA.

Lawrence Corey (L)

Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
Division of Allergy and Infectious Diseases, Department of Medicine, and.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH